SCHEDULE: Lipocine Inc. Ownership Update by Squadron Funds

Squadron Master Fund LP and its affiliates report a 6.2% stake in Lipocine Inc. common stock as of March 31, 2026.

Summary

• Squadron Master Fund LP, along with its investment advisor Squadron Capital Management, LLC, and partners Matthew Sesterhenn and William Blank, have reported beneficial ownership of 450,000 shares of Lipocine Inc. common stock.
• This holding represents 6.2% of the company's outstanding common stock, based on 7,299,687 shares outstanding as of March 9, 2026.
• The filing is an amendment to a Schedule 13G, indicating a passive investment stake.
• The reporting persons disclaim beneficial ownership beyond their direct investment activities, stating the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a significant passive investment but does not provide new operational or financial information about Lipocine Inc. itself.

Positives

• Significant passive stake (6.2%) reported by Squadron Master Fund LP, indicating investor confidence in Lipocine Inc.
• The filing confirms the shares were acquired and are held in the ordinary course of business, suggesting a stable, long-term investment approach.

Negatives

• The filing does not contain any negative financial or operational information about Lipocine Inc. itself, as it is an ownership disclosure.

Risks

• Potential for increased selling pressure if Squadron Master Fund LP decides to divest its stake.
• As a passive investment, there is no guarantee of continued support or strategic involvement from Squadron Master Fund LP.

Future Outlook

The filing does not contain forward-looking statements or guidance from Lipocine Inc. It is an ownership disclosure by a third-party investor.

Management Comments

• Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors taking significant, non-controlling stakes in publicly traded companies. This filing indicates Squadron Master Fund LP's interest in Lipocine Inc. within the broader biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, but the passive nature of the stake limits direct impact on corporate strategy.
• Management: The filing confirms a significant shareholder, which may influence future investor relations efforts.
• Creditors: No direct impact as this is an equity ownership disclosure.

Next Steps

• Monitor future filings from Squadron Master Fund LP for any changes in their stake.
• Observe Lipocine Inc.'s operational and financial performance for insights into the rationale behind this investment.

Key Dates

Keywords

Lipocine Inc., Schedule 13G, Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, William Blank, Beneficial Ownership, Common Stock, SEC Filing, Ownership Stake